Vertex Cystic Fibrosis Combo Wins Backing of U.S. Advisers

Vertex Pharmaceuticals Inc.’s experimental cystic fibrosis combination should be approved by U.S. regulators at the Food and Drug Administration, a panel of outside advisers said.

The panel voted 12-1 that a combination of an experimental drug, lumacaftor, and Vertex’s Kalydeco, which is already available, should be cleared for patients with the most common form of the lung disease. Vertex proposes calling the combination Orkambi.